Secondary Prevention of Osteoporosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy

NCT04861142

Osteoporosis

UNKNOWN

The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

NCT00346190

Osteoporosis

UNKNOWN PHASE3

Alendronate and/or Parathyroid Hormone for Osteoporosis

NCT00000400

Osteoporosis

COMPLETED PHASE2

Precision Medicine Approach for Osteoporosis - Follow Up Study

NCT06264609

Osteoporosis

ENROLLING_BY_INVITATION PHASE4

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

NCT00046254

Osteoporosis Hip Fracture

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following a fracture, few persons are screened or treated for osteoporosis (Feldstein et al). It is not surprising, then, that the risk of future osteoporotic fractures remains high. Although little data exists on the secondary prevention of osteoporosis, calcium, vitamin D, and bisphosphonates have all been shown to be effective in the primary prevention of osteoporotic fractures, and they are likely beneficial in reducing secondary fractures as well. Targeting falls prevention is another approach that is likely effective in reducing the risk of fracture.

In the U.S., acute rehabilitation (rehab) settings offer a unique environment to initiate osteoporotic therapy. Therefore, this study will develop and implement evidence based interventions for the secondary prevention of osteoporotic fractures in the acute rehab setting with the following objectives:

Specific Aim I: Assess overall compliance with pharmacological and non-pharmacological interventions initiated in an acute rehab setting following a fragility fracture. Hypothesis: Non-compliant participants are less likely to show improvement in functional status, muscle strength, or vitamin D levels following the intervention.

Specific Aim II: Describe the incidence of fragility fractures and falls in participants at 6-months and one-year following the osteoporotic intervention introduced during acute rehab. Hypothesis: Similar to community based studies, a number of participants will go on to experience repeat falls and resulting fractures within one-year of follow-up. Compliant participants are less likely to experience falls and fractures.

Specific Aim III: Confirm the high prevalence of vitamin D deficiency in a rehab setting. Describe the relationship between changes in vitamin D levels in participants between baseline and 6-month follow-up and changes in functional outcomes. Hypothesis: There will be a direct association between a change in vitamin D levels and a change in functional status.

Consecutive individuals admitted with the primary or secondary diagnosis of fracture in the rehabilitation unit of Hebrew Rehabilitation Center will be offered enrollment. All participants enrolled will receive the same intervention: calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention interventions. Specific interventions for preventing falls include optimization of visual acuity, a review of medications associated with falls, personalized exercises to improve strength and balance, and a home hazards safety evaluation when indicated.

All participants will have their functional status, muscle strength, and vitamin D level measured at baseline during their rehab stay. At the six-month follow-up, a home visit will be performed for all participants to again assess functional status, muscle strength, vitamin D level, satisfaction with the intervention, and reasons for non-compliance. A history of interim falls and fractures will be collected by telephone interviews, during home nursing visits, and during the exit 6-month visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment for osteoporosis and falls

calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention

Group Type OTHER

alendronate with cholecalciferol

Intervention Type DRUG

alendronate 70mg /cholecalciferol 2800IU orally once weekly

calcium carbonate with cholecalciferol

Intervention Type DRUG

calcium carbonate 500mg /cholecalciferol 200IU orally twice daily

Falls prevention measures

Intervention Type BEHAVIORAL

personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

alendronate with cholecalciferol

alendronate 70mg /cholecalciferol 2800IU orally once weekly

Intervention Type DRUG

calcium carbonate with cholecalciferol

calcium carbonate 500mg /cholecalciferol 200IU orally twice daily

Intervention Type DRUG

Falls prevention measures

personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fosamax Plus D® Os-Cal with extra D

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted to rehab unit with the primary or secondary diagnosis of fracture
* English speaking
* Cognitively able to provide consent or health care proxy available and willing to provide consent
* Willing to cooperate

Exclusion Criteria

* Pathologic or periprosthetic fractures
* Creatinine clearance less than 15ml/minute
* Severe hypocalcemia
* Esophageal stricture or achalasia
* Taking other treatment for osteoporosis besides calcium or vitamin D in the past 6-months
* History of kidney stones in the past 6-months

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No